Human hepatitis B virus core proteins as vaccine platforms...

Details Human hepatitis B virus core proteins as vaccine platforms... Human hepatitis B virus core proteins as vaccine platforms...

2006-12-05

2006-12-05

Mosher, Mary E. (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S471000, C435S091400, C435S091410, C435S235100, C435S320100, C424S189100, C424S192100

Reexamination Certificate

active

07144712

ABSTRACT:
The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

REFERENCES:
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4683136 (1987-07-01), Milich et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5726011 (1998-03-01), Milich et al.
patent: 5990085 (1999-11-01), Ireland et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6406705 (2002-06-01), Davis et al.
patent: 6518014 (2003-02-01), Seifer et al.
patent: 6602705 (2003-08-01), Barnett et al.
patent: 6887464 (2005-05-01), Coleman et al.
patent: 2003/0054337 (2003-03-01), Birkett
patent: 2003/0099668 (2003-05-01), Bachmann et al.
patent: 2003/0138769 (2003-07-01), Birkett
patent: 2003/0175296 (2003-09-01), Brown et al.
patent: 2003/0175863 (2003-09-01), Birkett
patent: 2003/0185854 (2003-10-01), Zavala et al.
patent: 2003/0185858 (2003-10-01), Birkett
patent: 2003/0198645 (2003-10-01), Page et al.
patent: 2003/0202982 (2003-10-01), Birkett
patent: 2004/0054139 (2004-03-01), Page et al.
patent: 2004/0146524 (2004-07-01), Lyons et al.
patent: 2004/0152876 (2004-08-01), Birkett
patent: 2004/0156864 (2004-08-01), Birkett
patent: 2004/0219164 (2004-11-01), Coleman et al.
patent: 7252300 (1995-10-01), None
patent: WO 95/27083 (1995-10-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 00/46365 (2000-08-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO/0198333 (2001-12-01), None
patent: WO 02/13765 (2002-12-01), None
Tarar, M.R. “Expression of a human cytomegalovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein” FEMS Immun. Med. Microbio. (1996) 16, 183-192.
Pumpens and Grens (2001) “HBV Core Particles as a Carrier for B Cell/T Cell Epitopes,” Intervirology 44:98-114.
Jegerlehner et al. “A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses,” (2002) Vaccine 20:3104.
Anderson and Young, Quantitative Filter Hybridization,in Nucleic Acid Hybridization[1985].
Smith and Waterman (1981) “Comparison of Biosequences,” Adv. Appl. Math. 2: 482-489.
Needleman and Wunsch (1970) “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol. 48: 443-453.
Pearson and Lipman (1988) “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci. U.S.A. 85:2444.
Sambrook et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp. 9.31-9.58, 1989.
Sambrook, et al., .Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp. 7.39-7.52, 1989.
GenBank Accession No. NKVLC2 printed Jul. 16, 1999.
GenBank Accession No. NP—040993 printed Dec. 8, 2002.
Winter and Milstein (1991) “Man-made antibodies,” Nature 349:293-299.
Böttcher et al. (1997) “Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy,” Nature 386:88-91.
Conway et al. (1997) “Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy,” Nature 386:91-94.
Salfeld et al. (1989) “Antigenic Determinants and Functional Domains in Core Antigen and e Antigen from Hepatitis B Virus,” J Virol. 63:798-808.
Schodel et al. (1992) “The Position of Heterologous Epitopes Inserted in Hepatitis B Virus Core Particles Determines Their Immunogenicity,” J Virol. 66:106-114.
Milich et al. (1995) “The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety,” Ann NY Acad Sci. 754:187-201.
Pumpens et al. (1995) “Hepatitis B Virus Core Particles as Epitope Carriers,” Intervirology 38:63-74.
Clarke et al. (1987) “Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein,” Nature 330:381-384.
Schodel et al. (1994) “Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes,” J Exp Med. 180:1037-1046.
Schodel et al. “Immunization with Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Antigen Epitopes Protects Mice AgainstPlasmodium yoeliiChallenge,” (1997) Behring Inst Mitt. 114-119.
Milich et al. (1997) “Role of B cells in antigen presentation of the hepatitis B core, ” Proc Natl Acad Sci USA 94:14648-14653.
Kratz et al. (1999) “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids, ” Proc Natl Acad Sci USA 96:1915-1920.
Chen et al. (2000) “Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4+ T-Cell Repertoire in Chronic Hepatitis B Virus Infection,” J. Virol. 74:7587-7599.
Lazdina et al. (2001) “Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells, ” J Virol. 75:6367-6374.
Cao et al. (2001) “Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model,” J Virol. 75:6359-6366.
Anttila et al. (1998) “Avidity of IgG forStreptococcus pneumoniaeType 6B and 23F Polysaccharides in Infants Primed with Pneumococcal Conjugates and Boosted with Polysaccharide or Conjugate Vaccines,” J Infect Dis. 177:1614-1621.
Arad et al. (2000) “Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation,” Nat Med. 6:414-421.
Visvanathan et al. (2001) “Inhibition of Bacterial Superantigens by Peptides and Antibodies,” Infect Immunol. 69:875-884.
DeVelasco et al. (1994) “Adjuvant Quil A improves protection in mice and enhaces opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines,” Vaccine 12:1419-1422.
Koletzki et al. (1997) “Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments,” J Gen Virol. 78:2049-2053.
Smiley and Minion (1993) “Enhanced readthrough of opal (UGA) stop codons and production ofMycoplasma pneumoniaeP1 epitopes inEscherichia coli,” Gene 134:33-40.
GenBank Accession No. NM 009778 printed Apr. 2003.
Dempsey et al. (1996) “C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity,” Science 271:348-350.
Tedder et al. (1994) “The CD19/CD21 signal transduction complex of B lymphocytes,” Immunol Today 15:437-442.
GenBank Accession No. X65453 printed Apr. 2001.
Morris et al. (1999) “Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154),” J. Biol. Chem. 274:418-423.
Mackay and Browning (2002) “Baff: A Fundamental Survival Factor for B Cells,” Nature Reviews Immunology 2:465-475.
GenBank Accession No. NM 008479 printed Apr. 2003.
El mir Triebel (2000) “A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens,” J. Immunol 164:5583-5589.
Krieg et al. (1995) “CpG motifs in bacterial DNA trigger direct B-cell activation,” Nature 374:546-549.
Davis et al. (1998) “CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen,” J. Immunol. 160:870-876.
Fouet et al. (1999) “Bacillus anthracissurface: capsule and S-layer,” Appl Microbiol. 87:251-255.
Paoletti et al. (2002) “Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with

Affiliated with

Also associated with

Rating

Human hepatitis B virus core proteins as vaccine platforms... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human hepatitis B virus core proteins as vaccine platforms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human hepatitis B virus core proteins as vaccine platforms... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3679379